Updated with stock prices.
It’s Monday, which means Wall Street is having a say about the results from a long-anticipated clinical trial of the cholesterol-lowering drug Praluent that were presented Saturday by Regeneron Pharmaceuticals and Sanofi.
Praluent, given by injection, reduced the risk of death for patients with high cholesterol — a landmark finding in the field of cardiology, doctors said, marking the first time since the statin era that a cholesterol-lowering drug has demonstrated a significant effect on whether patients live or die.
Read article
RT